StreetInsider.com News Articles

Climb Bio (CLYM) PT Raised to $30 at H.C. Wainwright

Tue, 08 Sep 2026 07:38:03 -0400

(Updated - September 8, 2026 7:38 AM EDT)

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Climb Bio (NASDAQ: CLYM) to $30.00 (from $24.00) while maintaining a Buy rating.

The analyst commented: "As presented last week, CLYM116 showed dose-proportional exposure, linear clearance above 1 µg/mL, and no observed target-mediated drug disposition at clinically relevant concentrations. Based on the 320mg multiple ascending dose (MAD) cohort, Climb projects an approximately 29-day half-life. A single 320mg dose suppressed free APRIL by >90% through Week 10 and more than 75% at Week 12, with ~60% IgA, >70% Gd-IgA1, and ~75% IgM reductions maintained through

Climb Bio (CLYM) PT Raised to $30 at H.C. Wainwright

Tue, 08 Sep 2026 07:38:03 -0400

(Updated - September 8, 2026 7:38 AM EDT)

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Climb Bio (NASDAQ: CLYM) to $30.00 (from $24.00) while maintaining a Buy rating.

Climb Bio (CLYM) PT Raised to $25 at Oppenheimer

Tue, 08 Sep 2026 07:14:10 -0400

Oppenheimer analyst Leland Gershell raised the price target on Climb Bio (NASDAQ: CLYM) to $25.00 (from $18.00) while maintaining a Outperform rating.

The analyst comments "The recent CLYM116 reveal illustrates a best-in-class clinical profile for IgAN as echoed by our KOL discussion. Clear Q12W dosing support with IgA suppression to typical anti-APRIL depths put CLYM116 on solid competitive footing to JBIO's JADE101 among other class members, and safety featured no surprises. An initial look from partner Mabworks' Phase 2 in IgAN patients is on track for 1H, and Phase 3 is slated to begin next year. We believe CLYM116 is shaping

Climb Bio (CLYM) PT Raised to $25 at Oppenheimer

Tue, 08 Sep 2026 07:14:10 -0400

Oppenheimer analyst Leland Gershell raised the price target on Climb Bio (NASDAQ: CLYM) to $25.00 (from $18.00) while maintaining a Outperform rating.

Climb Bio (CLYM) PT Raised to $30 at B.Riley

Fri, 04 Sep 2026 08:24:56 -0400

B.Riley analyst Mayank Mamtani raised the price target on Climb Bio (NASDAQ: CLYM) to $30.00 (from $26.00) while maintaining a Buy rating.

Climb Bio (CLYM) PT Raised to $32 at BTIG

Thu, 03 Sep 2026 13:21:00 -0400

BTIG analyst Julian Harrison raised the price target on Climb Bio (NASDAQ: CLYM) to $32.00 (from $20.00) while maintaining a Buy rating.

The analyst comments "CLYM116's Phase 1 results were within our positive previewed scenario, with CLYM116 showing the potential for Q12W dosing and ~55% IgA reduction at 12wk seen with the 320mg dose (most comparable to VOYXACT commercial dose and JADE101 350mg dose). CLYM116 showed rapid and sustained free APRIL (fAPRIL) suppression, with >90% suppression through 10wk and >75% suppression maintained through 12wk. No ADA data were shared, although mgmt. noted there has been nothing seen from the existing data

Climb Bio (CLYM) PT Raised to $32 at BTIG

Thu, 03 Sep 2026 13:21:00 -0400

BTIG analyst Julian Harrison raised the price target on Climb Bio (NASDAQ: CLYM) to $32.00 (from $20.00) while maintaining a Buy rating.

Climb Bio (CLYM) PT Raised to $25 at Baird

Thu, 03 Sep 2026 12:15:37 -0400

Baird analyst Mayank Mamtani raised the price target on Climb Bio (NASDAQ: CLYM) to $25.00 (from $21.00) while maintaining a Outperform rating.

The analyst comments "Raising target on differentiated PK/PD data. The Ph1 data for CLYM116 are encouraging, with near-complete APRIL suppression and impressive reductions in IgA and Gd-IgA1 in healthy volunteers. We think this suggests a profile that is likely similar to earlier-gen anti-APRILs but with a substantially longer half life. With initial Ph2 data 1H27 and a planned 2027 Ph3 initiation, we see a nice pacing of data for the program. We're raising our probability of success to 50%

Climb Bio (CLYM) PT Raised to $25 at Baird

Thu, 03 Sep 2026 12:15:37 -0400

Baird analyst Mayank Mamtani raised the price target on Climb Bio (NASDAQ: CLYM) to $25.00 (from $21.00) while maintaining a Outperform rating.

Climb Bio reports Phase 1 data for CLYM116 in IgA nephropathy

Thu, 03 Sep 2026 07:00:37 -0400

Climb Bio, Inc. (Nasdaq: CLYM) released initial Phase 1 data for CLYM116, an anti-APRIL monoclonal antibody being developed for IgA nephropathy (IgAN), according to a company statement.

The Phase 1 trial was a randomized, double-blind, placebo-controlled, single- and multiple-ascending-dose study enrolling 46 healthy volunteers. It evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous CLYM116.

Key findings include a projected half-life of approximately 29 days based on the 320 mg multiple-ascending-dose cohort. A single 320 mg dose produced greater than 90% free APRIL suppression and approximately 60–75% suppression of IgA, Gd-IgA1, and IgM, with suppression maintained through 12 weeks. The company reported

Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy

Thu, 03 Sep 2026 07:00:00 -0400

~29-day half-life

Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks

CLYM116 generally well-tolerated, with no serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia

Phase 2 NAVIGATE-2 trial in IgA nephropathy ongoing; anticipate initial data in H1 2027, Phase 3 study initiation in 2027

Company to host R&D Spotlight Webcast today, September 3 at 8:00 a.m. ET

WELLESLEY HILLS, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics

Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy

Thu, 03 Sep 2026 07:00:00 -0400

~29-day half-life

Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks

CLYM116 generally well-tolerated, with no serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia

Phase 2 NAVIGATE-2 trial in IgA nephropathy ongoing; anticipate initial data in H1 2027, Phase 3 study initiation in 2027

Company to host R&D Spotlight Webcast today, September 3 at 8:00 a.m. ET

WELLESLEY HILLS, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics

Climb Bio to Present at Upcoming Investor Conferences

Wed, 02 Sep 2026 07:00:00 -0400

WELLESLEY HILLS, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below.

Wells Fargo 21st Annual Healthcare Conference
Format: Fireside Chat
Date: Wednesday, September 9
Time: 4:30 – 5:05 p.m. ET

Morgan Stanley 24th Annual Global Healthcare Conference
Format: Fireside Chat
Date: Wednesday, September 16
Time: 8:30 – 9:05 AM a.m. ET

The live webcasts will be accessible via the “Investors & Media”

Climb Bio to Present at Upcoming Investor Conferences

Wed, 02 Sep 2026 07:00:00 -0400

Wells Fargo 21st Annual Healthcare Conference
Format: Fireside Chat
Date: Wednesday, September 9
Time: 4:30 – 5:05 p.m. ET

Morgan Stanley 24th Annual Global Healthcare Conference
Format: Fireside Chat
Date: Wednesday, September 16
Time: 8:30 – 9:05 AM a.m. ET

The live webcasts will be accessible via the “Investors & Media”

Climb Bio (CLYM) PT Raised to $24 at H.C. Wainwright

Mon, 24 Aug 2026 06:49:20 -0400

(Updated - August 24, 2026 6:49 AM EDT)

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Climb Bio (NASDAQ: CLYM) to $24.00 (from $20.00) while maintaining a Buy rating.

The analyst commented: "We remind investors that Climb Bio is slated to host a webcast on September 3, 2026 to review the initial Phase 1 PK/PD data and development plans for CLYM116, its second pipeline candidate, in the treatment of IgA nephropathy (IgAN). CLYM116 is a novel anti-APRIL antibody with the potential for less-frequent dosing than existing commercially-available therapies used in IgAN. Multiple drugs have been approved to treat IgAN, including

Climb Bio (CLYM) PT Raised to $24 at H.C. Wainwright

Mon, 24 Aug 2026 06:49:20 -0400

(Updated - August 24, 2026 6:49 AM EDT)

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Climb Bio (NASDAQ: CLYM) to $24.00 (from $20.00) while maintaining a Buy rating.

Form SCHEDULE 13G/A Climb Bio, Inc. Filed by: MPM BioImpact LLC

Fri, 14 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26930072.html

Form SCHEDULE 13G/A Climb Bio, Inc. Filed by: MPM BioImpact LLC

Fri, 14 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26930072.html

Form 8-K Climb Bio, Inc. For: Aug 13

Fri, 14 Aug 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260814/26925140.html

Form 8-K Climb Bio, Inc. For: Aug 13

Fri, 14 Aug 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260814/26925140.html

Climb Bio, Inc. (CLYM) Tops Q2 EPS by 3c

Thu, 06 Aug 2026 08:04:26 -0400

Climb Bio, Inc. (NASDAQ: CLYM) reported Q2 EPS of ($0.18), $0.03 better than the analyst estimate of ($0.21).

For earnings history and earnings-related data on Climb Bio, Inc. (CLYM) click here.

Form 10-Q Climb Bio, Inc. For: Jun 30

Thu, 06 Aug 2026 07:46:00 -0400

si-local-file:///var/storage/secattach/20260806/26878974.html

Form 10-Q Climb Bio, Inc. For: Jun 30

Thu, 06 Aug 2026 07:46:00 -0400

si-local-file:///var/storage/secattach/20260806/26878974.html

Form 8-K Climb Bio, Inc. For: Aug 06

Thu, 06 Aug 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260806/26878892.html

Form 8-K Climb Bio, Inc. For: Aug 06

Thu, 06 Aug 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260806/26878892.html